Marshallagia marshalli Antigen Strengthens Dendritic Cell Mediated T Lymphocyte Regulation on Asthmatic Patients

Background: The current study was conducted to investigate the antigenic effect of Marshallagia marshalli on the treatment of asthma by measuring the secreted inhibitory cytokine. Methods: Case patients and controls were selected from clinics in Mashhad, Khora-san Razavi Province, Northeastern Iran in 2017-18. In this experimental study, pe-ripheral blood mononuclear cells (PBMCs) were isolated from 15 patients with asth-ma and 10 healthy controls and were cultured. PBMCs were then converted to toler-ogenic DCs through exposure to GM-CSF, IL-4 and M. marshalli antigen. Then, tolerogenic DCs were exposed to autologous T cells for five days and finally, the level of secreted TGF-β1 was measured. Results: The mean TGF-β1 level in the control and control groups was 210.2 ± 8.2 and 225.4 ± 6.1 pq/ml, respectively. The results showed that TGF-β1 levels in both groups significantly increased in both groups (P<0.001). In addition, TGF-β1 levels in the case group were significantly higher than the control group (P<0.001). Conclusion: M. marshalli antigen increase the level of TGF-β1 and can create anti-gen-bearing dendritic cells and shift T lymphocytes to the regulatory type. This para-site can be used in dendritic cell therapy to control allergic diseases.